Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Nvidia Sinks

Nvidia (NVDA) posted 3 cents, vs. 14 cents second-quarter EPS on a slight revenue drop. The maker of integrated graphics chipsets says the desktop graphics-processing unit segment declined significantly due to "unusual" market events. Wedbush Morgan downgraded to hold from buy. CIBC World and Schwab SoundView cut its estimates.

ESpeed (ESPD) posted 16 cents, vs. 15 cents second-quarter earnings per share (GAAP) on a 9.5% revenue rise. It sees third-quarter earnings per share from operations of 9 cents to 10 cents. Jefferies downgraded to underperform from hold.

Hollywood Entertainment (HLYW) says Leonard Green & Partners, its wholly owned subsidiary (the entities with which Hollywood Entertainment entered into a merger agreement on March 29, 2004), believes the financing condition to complete the merger will not be satisfied.

Chiquita Brands (CQB) posted 73 cents, vs. $1.41 second-quarter earnings per share as charges in the current quarter, absence of gains vs. a year ago, offset a 2.3% sales rise.

Elizabeth Arden (RDEN) posted a 35-cent second-quarter loss, vs. a 90-cent loss on a 17% revenue rise. The beauty company sees $900 million to $910 million in fiscal 2005 sales and $1.24 to $1.28 earnings per share.

WebMD (HLTH) posted 2 cents, vs. 2 cents second-quarter earnings per share from continuing operations despite a 21% revenue rise. The medical-information Website sees 12 cents to 13 cents 2004 earnings per share on revenue of $1.145 billion to $1.155 billion. It says it will explore alternatives for its WebMD Health business.

Dov Pharmaceuticals (DOVP) inked a deal with Merck (MRK) to develop and commercialize Dov's novel triple uptake inhibitors for depression and related psychiatric disorders. The company will get a $35 million up-front payment.

MCI (MCIP) posted a narrower-than-expected 22-cent second-quarter loss on a 15% revenue decline. The board declared excess cash of $2.2 billion, and initiated return of capital in the form of a quarterly dividend of 40 cents per share, payable Sept. 15.

Microvision (MVIS) posted a 40-cent second-quarter loss, vs. a 38-cent loss on a 47% revenue decline, citing production and contract delays.

Gen-Probe (GPRO) posted 23 cents, vs. 17 cents second-quarter earnings per share on a 21% revenue rise, and raised the 2004 earnings per share guidance to 97 cents to $1.00.

O'Charley's (CHUX) posted 23 cents, vs. 27 cents second-quarter earnings per share on a 12% revenue rise. The restaurant operator estimated that increased commodity costs reduced earnings per share by about 8 cents, and it sees 20 cents to 22 cents third-quarter earnings per share.

Amgen 's (AMGN) Aranesp received a positive regulatory opinion for extended dosing in the European Union.

Thoratec (THOR) received FDA approval of its Pre-Market Approval Supplement to market the Thoratec implantable ventricular assist device, or IVAD, in the U.S.

Newfield Exploration (NFX) acquired Inland Resources in a $575 million deal.

Old Dominion (ODFL) sees 48 cents to 50 cents third-quarter earnings per share, and raised the 2004 earnings per share guidance to $1.55 to $1.59.

Ceridian (CEN) will delay its Form 10-Q for the second quarter pending completion of an internal review focusing on capitalization and the expensing of certain costs in its U.S. Human Resource Solutions business.

Gemstar-TV Guide (GMST) posted 10 cents second-quarter earnings per share from continuing operations, vs. a 7-cent loss as lower operating costs offset flat revenue.

Orasure Technologies (OSUR) says the U.S. Substance Abuse and Mental Health Services Administration will purchase $4 million worth of its OraQuick Rapid HIV Antibody Tests and HIV confirmatory-test services.

blog comments powered by Disqus